Exploring Novel Therapies for Relapsed/Refractory Multiple Myeloma

This AJMC Peer Exchange® program, moderated by Ryan Haumschild, PharmD, MS, MBA, brings together clinical pharmacy specialists Shahrier Hossain, PharmD; Michael Singel, PharmD; and hematologist Naresh Bumma, MD, to explore how emerging therapies are reshaping care for relapsed/refractory multiple myeloma (RRMM). The panel reviews disease biology, conventional first-line and later-line options, and then dives into bispecific antibodies—including linvoseltamab, teclistamab, talquetamab, and elranatamab—covering mechanisms of action, pivotal approval data, dosing schedules, and toxicity management. They close by comparing operational considerations across bispecifics and CAR T therapies, emphasizing practical dosing, CRS/ICANS management, and the biggest unmet needs and future advances expected over the next 5 years.